SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Core Working Party for the Asia-Pacific consensus on hepatitis B, C. Consensus statements on the prevention and management of hepatitis B and hepatitis C in the Asia-Pacific region. J. Gastroenterol. Hepatol. 2000; 15: 82541.
  • 2
    Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology 2001; 34: 122541.
  • 3
    Liaw YF, Tsai SL. Pathogenesis and clinical significance of acute exacerbation and remissions in patients with chronic hepatitis B virus infection. Viral Hep. Rev. 1997; 3: 14354.
  • 4
    Hsu YS, Chien RN, Yeh CT et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002; 35: 15227.
  • 5
    Kao JH. Hepatitis B viral genotypes: clinical relevance and molecular characteristics. J. Gastroenterol. Hepatol. 2002; 17: 64350.
  • 6
    Guan R. Interferon monotherapy in chronic hepatitis B. J. Gastroenterol. Hepatol. 2000; 15 (Suppl.): E34E40.
  • 7
    Sokal E. Drug treatment of pediatric chronic hepatitis B. Paediatr. Drugs 2002; 4: 3619.
  • 8
    Lai MY, Cooksley WGE, Piratvisuth T et al. Efficacy and safety of peginterferon alfa-2A (40KD) (PEGASYS®) in HBeAg-positive chronic hepatitis B (CHB): 48-week results from a phase II study. J. Gastroenterol. Hepatol. 2002; 17 (Suppl.): A27.
  • 9
    Krogsgaard K, Marcellin P, Trepo C et al. Prednisone withdrawal therapy enhances the effect of human lymphoblastoid interferon in chronic hepatitis B. Interpred Trial Group. J. Hepatol. 1996; 25: 80313.
  • 10
    Yokosuka O. Role of steroid priming in the treatment of chronic hepatitis B. J. Gastroenterol. Hepatol. 2000; 15 (Suppl.): E41E45.
  • 11
    Perrillo RP. Chronic hepatitis B problem patients (including patients with decompensated disease). J. Hepatol. 1995; 22 (Suppl.): 458.
  • 12
    Niederau C, Heintges T, Lange S et al. Long term follow-up of HBeAg positive patients treated with interferon alpha for chronic hepatitis B. N. Engl. J. Med. 1996; 334: 14227.
  • 13
    Lin SM, Sheen IS, Chien RN et al. Long term beneficial effects of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999; 29: 9715.
  • 14
    Manesis EK, Hadziyannis SJ. Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 2001; 121: 1019.
  • 15
    Perrillo RP, Tamburro C, Regenstein F et al. Low dose titratable IFN alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology 1995; 109: 90816.
  • 16
    Chien RN, Liaw YF, Chen TC, Yeh CT, Sheen IS. Efficacy of thymosin α1 in patients with chronic type B hepatitis: a randomized controlled trial. Hepatology 1998; 27: 13837.
  • 17
    Lau GKK. Use of immunomodulatory therapy (non-interferon) for the treatment of chronic hepatitis B virus infection. J. Gastroenterol. Hepatol. 2000; 15 (Suppl.): E46E52.
  • 18
    Leung N. Nucleoside analogues in the treatment of chronic hepatitis B. J. Gastroenterol. Hepatol. 2000; 15 (Suppl.): E53E60.
  • 19
    Lai CL, Chien RN, Leung NW et al. A one-year trial of lamivudine for chronic hepatitis B. N. Engl. J. Med. 1998; 339: 618.
  • 20
    Dienstag JL, Schiff ER, Wright TL et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N. Engl. J. Med. 1999; 341: 125663.
  • 21
    Tassopoulos NC, Volpes R, Pastore G et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 1999; 29: 88996.
  • 22
    Chien RN, Liaw YF, Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Hepatology 1999; 30: 7704.
  • 23
    Jonas MM, Kelley DA, Mizerski J et al. Clinical trial of lamivudine in children with chronic hepatitis B. N. Engl. J. Med. 2002; 346: 170613.
  • 24
    Honkoop P, DeMan RA, Niesters HGM et al. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 2000; 32: 6359.
  • 25
    Guan R, Lai CL, Liaw YF et al. Efficacy and safety of 5 years lamivudine treatment of Chinese patients with chronic hepatitis B. J. Gastroenterol. Hepatol. 2001; 16 (Suppl.): A60.
  • 26
    Song BC, Suh DJ, Lee HC et al. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000; 32: 8036.
  • 27
    Villeneuve JP, Condreay LD, Willems B et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000; 31: 20710.
  • 28
    Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999; 30: 56772.
  • 29
    Schalm SW, Heathcote J, Cianciara J et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000; 46: 5628.
  • 30
    Barbaro G, Zechnini F, Pellicelli AM et al. Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial. J. Hepatol. 2001; 35: 40611.
  • 31
    Perrillo R, Schiff E, Yoshida E, Statler A et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000; 32: 12934.
  • 32
    Tassopoulos N, Hadziyannis S, Cianciara J et al. Entecavir is effective in treating patients with chronic hepatitis B who have failed lamivudine therapy. Hepatology 2001; 34: 340A.
  • 33
    Yang H, Westland CE, Delaney WE et al. Lack of emerging resistance mutations in 467 HBeAg-negative and HBeAg positive patients with chronic hepatitis B receiving adefovir dipivoxil for 48 weeks. J. Hepatol. 2002; 36 (Suppl.): 137.
  • 34
    Wang BE. Treatment of chronic liver disease with traditional Chinese medicine. J. Gastroenterol. Hepatol. 2000; 15 (Suppl.): E67E70.
  • 35
    Yao FY, Bass NM. Lamivudine treatment in patients with severely decompensated cirrhosis due to repli-cating hepatitis B infection. J. Hepatol. 2000; 33: 3017.
  • 36
    Perrillo RP, Wright T, Rakela J et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001; 33: 42432.
  • 37
    Liu CJ, Lai MY, Lee PH et al. Lamivudine treatment for hepatitis B reactivation in HBsAg carriers after organ transplantation: a 4-year experience. J. Gastroenterol. Hepatol. 2001; 16: 10018.
  • 38
    Rossi G, Pelizzari A, Motta M, Puoti M. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HBsAg carriers with lymphoid malignancies treated with chemotherapy. Br. J. Haematol. 2001; 115: 5862.
  • 39
    Lau GKK, He ML, Fong DY et al. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogemic hematopoietic cell transplantation. Hepatology 2002; 36: 7029.
  • 40
    Chan TM, Fang GX, Tang CS, Cheng IK, Lai KN, Ho SK. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients. Hepatology 2002; 36: 124652.
  • 41
    Lin DY, Liaw YF. Optimal surveillance of hepatocellular carcinoma in patients with chronic viral hepatitis. J. Gastroenterol. Hepatol. 2001; 16: 7157.
  • 42
    Santantonio T, Mazzola M, Iacovazzi T, Miglietta A, Guastadisegni A, Pastore G. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J. Hepatol. 2000; 32: 3006.
  • 43
    Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. To continue or not continue lamivudine therapy after emergence of YMDD mutations? Gastroenterology 2002; 122: A628.
  • 44
    Wong VWS, Chan HLY, Wong ML, Leung N. Is it safe to stop lamivudine after the emergence of YMDD mutants during lamivudine therapy for chronic hepatitis B? J. Hepatol. 2002; 36 (Suppl.): 177.